A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 11, 1998, Pages 1079-1089

  Williams, M P ^a   Sercombe, J ^a   Hamilton, M I ^a   Pounder, R E ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 13; GASTRIN; LY 307640; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; UNCLASSIFIED DRUG; UREA;

ADULT; ARTICLE; BREATH ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GASTRIN BLOOD LEVEL; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH; STOMACH SUCTION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADENOSINE TRIPHOSPHATASES; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; GASTRINS; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; RADIOIMMUNOASSAY; STATISTICS, NONPARAMETRIC;

EID: 0031767238     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00418.x     Document Type: Article

References (47)

1. +-ATPase. Biochem Pharmacol 1995; 49: 1729-34.
2. + ATPase by E3810. Chem Pharm Bull 1996; 44: 552-8.
3. Fujisaki H, Shibata H, Oketani K, et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991; 42: 321-8.
4. Fujisaki H, Shibata H, Oketani K, et al. Effects of the proton pump inhibitor, E3820, on gastric secretion and gastric duodenal ulcers or erosions in rats. Drug Invest 1991; 3: 328-32.
5. Kovacs EJ, Syntnik B, Humphries TJ, Walsh JH. A low dose of a new proton pump inhibitor, LY307640 (E3810) effectively inhibits acid secretion in humans. Gastroenterology 1996; 110(4): A240(Abstract).
6. Robinson M, Maton PN, Rodruigez S, Greenwood B, Humphries TJ. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 973-80.
7. Blanshard C, Millson C, Sercombe J, Pounder RE. The effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin concentration in healthy subjects. Gut 1996; 39(Suppl. 3): A47(Abstract).
8. Cloud ML, Enas N, Humphries T, Bassion S, and the Rabeprazole Study Group. Results of three placebo-controlled clinical trials in duodenal ulcer, gastric ulcer and gastroesophageal reflux disease. Dig Dis Sci 1998; 43: 993-1000.
9. Humphries TJ, Spera A, Brieter J, et al. Rabeprazole sodium once daily is superior to ranitidine 150 mg bid in the healing of active duodenal ulcer. Gastroenterology 1997; 112(4): A154(Abstract).
10. Humphries T, Spera AC, Breiter J, et al. Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg qid in the healing of erosive or ulcerative gastroesophageal reflux disease. Gastroenterology 1996; 110(4): A240(Abstract).
11. McTavish D, Buckley MM-T, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid related disorders. Drugs 1991; 42: 138-70.
12. van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of Helicobacter pylori infection: A review of world literature. Helicobacter 1996; 1: 6-19.
13. Verdú EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
14. Verdú EF, Armstrong D, Idström J-P, et al. Effect of curing Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 37: 743-8.
15. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
16. Cederberg C, Röhss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 18: 179-84.
17. Dekkers CPM, Beker JA, Thjodleifsson B, Cabryelewicz A, Bell NE, Humphries TJ. and the European Rabeprazole Study Group. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer - a European multicentre study. Aliment Pharm Ther 1998; 12: 789-795.
18. Dekkers CPM, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Rabeprazole sodium 20 mg once daily is similar to omeprazole 20 mg once daily in the healing of gastric ulcer. Gastroenterology 1997; 112(4): A99(Abstract).
19. Thjodleifsson B, Beker JA, Dekkers CPM, et al. Omeprazole sodium 20 mg once daily is similar to omeprazole 20 mg once daily in the treatment of ulcerative GERD. Gastroenterology 1997; 112(4): A312(Abstract).
20. 13C-UBT for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1991; 3: 915-21.
21. 13C-urea breath test. Gastroenterology 1996; 110(4): A144(Abstract).
22. Bryant MG, Adrian TE. Gastrin. In: Bloom SR, Long RG, eds. Radioimmunoassay of Gut Regulatory Peptides. London: Saunders, 1982: 51-9.
23. Pounder RE, Lanzon-Miller S, Smith JTL, et al. Royal Free Protocol for 24-hour intragastric acidity and plasma gastrin concentration. Dig Dis 1990; 8(Suppl. 1): 10-1
24. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barretts's oesophagitis. Gut 1997; 40: 9-13.
25. Mihara M, Haruma K, Kamada T, et al. Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis. Gut 1996; 39(Suppl. 2): A94(Abstract).
26. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9(Suppl. 2): 45-51.
27. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
28. Anon. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. Gut 1997; 41: 8-13.
29. Geus WP, Mulder PGH, Nicolai JJ, Van der Boomgaard DM, Lamers CBHW. Acid-inhibitory effects of omeprazole and lansoprazole in Helicobacter pylori-negative healthy subjects. Aliment Pharmacol Ther 1998; 12: 329-35.
30. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression in healing duodenal ulcer? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
31. Bell NJ, Burget D, Howden C, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 56-67.
32. Lanzon-Miller S, Pounder RE, Hamilton MR, et al. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1987; 1: 259-51.
33. Lind T, Cederberg C, Idström J-P, Lönroth H, Olbe L, Lundell L. 24-hour intragastric acidity and plasma gastrin during long-term treatment with omeprazole or ranitidine in patients with retlux esophagitis. Scand J Gastroenterol 1991; 26: 620-6.
34. Huber R, Kohl B, Sachs G, Senn-Bilfinfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 363-78.
35. Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45-52.
36. Hartmann M, Thieß U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics follwoing single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 359-6.
37. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994; 32: 466-73.
38. Verdú EF, Armstrong D, Idström J-P, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1551-6.
39. Cave DR, Vargas M. Effect of Campylobacter pylori protein on acid secretion by parietal cells. Lancet 1989; ii: 187-9.
40. +-ATPase. Gut 1994; 35: 1176-80.
41. Gillen D, Wirz A, McColl KEL. Degree of acid suppression of gastric acid secretion by omeprazole is related to H. pylori status. Gastroenterology 1997; 112: A126 (Abstract).
42. Healey ZV, Bliss P, Arebi N, Hussain Z, Atherton J, Calam J. The acid inhibitory actions of Helicobacter pylori and IL1β on isolated rabbit parietal cells are additive to that of omeprazole. Gut 1997; 41(Suppl. 3): A112( Abstract).
43. Labenz J, Tillenburg B, Peitz U, et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997; 41: 33-66.
44. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22438-46.
45. De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology 1986; 91: 333-7.
46. Smith JTL, Pounder RE, Nwokolo CU, et al. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522-5.
47. El-Omar EM, Penman ID, Ardill JES, Chittajallu RS, Howie C, McColl KEL. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.